Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 7 » Issue 1

Polypharmacy or medication washout: an old tool revisited

Authors Hoffman DA, Schiller M, Greenblatt JM, Iosifescu DV

Published Date October 2011 Volume 2011:7(1) Pages 639—648


Published 20 October 2011

Daniel A Hoffman1, Mark Schiller2, James M Greenblatt3, Dan V Iosifescu4
1Neuro-Therapy Clinic Inc, Denver, CO; 2Mind Therapy Clinic, 2299 Post Street, Suite 104A, San Francisco, CA; 3Comprehensive Psychiatric Resources, Waltham, MA; 4Mood and Anxiety Disorders Program, Mount Sinai School of Medicine, New York, NY, USA

Abstract: There has been a rapid increase in the use of polypharmacy in psychiatry possibly due to the introduction of newer drugs, greater availability of these newer drugs, excessive confidence in clinical trial results, widespread prescribing of psychotropic medications by primary care, and pressure to augment with additional medications for unresolved side effects or greater efficacy. Even the new generation of medications may not hold significant advantages over older drugs. In fact, there may be additional safety risks with polypharmacy being so widespread. Washout, as a clinical tool, is rarely done in medication management today. Studies have shown that augmenting therapy with additional medications resulted in 9.1%–34.1% dropouts due to intolerance of the augmentation, whereas studies of medication washout demonstrated only 5.9%–7.8% intolerance to the washout procedure. These perils justify reconsideration of medication washout before deciding on augmentation. There are unwarranted fears and resistance in the medical community toward medication washout, especially at the moment a physician is trying to decide whether to washout or add more medications to the treatment regimen. However, medication washout provides unique benefits to the physician: it establishes a new baseline of the disorder, helps identify medication efficacy from their adverse effects, and provides clarity of diagnosis and potential reduction of drug treatments, drug interactions, and costs. It may also reduce overall adverse events, not to mention a potential to reduce liability. After washout, physicians may be able to select the appropriate polypharmacy more effectively and safely, if necessary. Washout, while not for every patient, may be an effective tool for physicians who need to decide on whether to add potentially risky polypharmacy for a given patient. The risks of washout may, in some cases, be lower and the benefits may be clearly helpful for diagnosis, understanding medication effects, the doctor/patient relationship, and safer use of polypharmacy if indicated.

Keywords: polypharmacy, medication washout, risk of polypharmacy

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Readers of this article also read:

Choroidal thinning in high myopia measured by optical coherence tomography

Ikuno Y, Fujimoto S, Jo Y, Asai T, Nishida K

Clinical Ophthalmology 2013, 7:889-893

Published Date: 15 May 2013

Rapid anterior capsular contraction after phacoemulsification surgery in a patient with retinitis pigmentosa

Jin-Poi T, Shatriah I, Khairy-Shamel ST, Zunaina E

Clinical Ophthalmology 2013, 7:839-842

Published Date: 6 May 2013

Preparation for high-acuity clinical placement: confidence levels of final-year nursing students

Porter J, Morphet J, Missen K, Raymond A

Advances in Medical Education and Practice 2013, 4:83-89

Published Date: 30 April 2013

Worsened hypertension control induced by aripiprazole

Yasui-Furukori N, Fujii A

Neuropsychiatric Disease and Treatment 2013, 9:505-507

Published Date: 15 April 2013

Parkinson’s disease patients’ subjective descriptions of characteristics of chronic pain, sleeping patterns and health-related quality of life

Skogar Ö, Fall P-A, Hallgren G, Bringer B, Carlsson M, Lennartsson U, Sandbjörk H, Törnhage C-J, Lökk J

Neuropsychiatric Disease and Treatment 2012, 8:435-442

Published Date: 12 October 2012

Role of aripiprazole in treatment-resistant schizophrenia

Mossaheb N, Kaufmann RM

Neuropsychiatric Disease and Treatment 2012, 8:235-244

Published Date: 29 May 2012

Retrospective chart review of a referenced EEG database in assisting medication selection for treatment of depression in patients with eating disorders

Greenblatt JM, Sussman C, Jameson M, Yuan L, Hoffman DA, Iosifescu DV

Neuropsychiatric Disease and Treatment 2011, 7:529-541

Published Date: 9 September 2011

Noradrenergic symptom cluster in depression

Montgomery S, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:1-2

Published Date: 31 May 2011

The importance of norepinephrine in depression

Moret C, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:9-13

Published Date: 31 May 2011